Sutro Biopharma (STRO) Return on Equity (2018 - 2025)

Sutro Biopharma's Return on Equity history runs 8 years deep, the most recent figure standing at 0.02% for Q4 2025.

• In Q4 2025, Return on Equity rose 2.0% year-over-year to 0.02%; the TTM figure through Dec 2025 stood at 0.02% (up 2.0% YoY), while the FY2025 annual figure was 0.04%, up 4.0% from the prior year.
• Return on Equity came in at 0.02% for Q4 2025 at Sutro Biopharma, up from 0.0% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.02% in Q4 2025 to a low of 0.01% in Q3 2023.
• A 5-year average of 0.01% and a median of 0.01% in 2022 frame the typical range for Return on Equity.
• Across the five-year window, Return on Equity retreated 1 bps in 2023 and increased 2 bps in 2025, its largest moves.
• Sutro Biopharma's Return on Equity stood at 0.0% in 2021, then plunged by 51 bps to 0.01% in 2022, then sank by 53 bps to 0.01% in 2023, then soared by 96 bps to 0.0% in 2024, then jumped by 5432 bps to 0.02% in 2025.
• According to Business Quant data, Return on Equity over the past three periods registered 0.02%, 0.0%, and 0.01% for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison